<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Discussing the Management of KRAS Inhibitors in NSCLC

minute read

by Targeted Oncology | June 28, 2023
placeholder

During a Targeted Oncology Case-Based Roundtable event, D. Ross Camidge, MD, PhD, discussed dosing and toxicity concerns with the KRAS inhibitors adagrasib and sotorasib.

Topics: Press Coverage

Comments